Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in FibromyalgiaIrwin Naturals Bringing Its Household Name Brand to the Psychedelic Mental Health SpaceTryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETFMindMed and Liechti Lab Provide Results from their Psilocybin R&D CollaborationPsyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating DisordersPsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research Collaboration

Technical420 Site Search

Returned 15 result(s).

Numinus Wellness Is Taking Strides To Advance Its R&D Business Unit

The psychedelic therapy market is one of the most exciting emerging industries and is a vertical that we have been highly focused on. We expect 2021 to be a transformational year for the psychedelic sector as companies prepare to report Phase 3 clinical trial data. We expect positive phase 3…

Numinus to expand state-of-the-art psychedelics research laboratory

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), is pleased to announce plans to significantly expand its psychedelics research laboratory by late 2021. A 7,500 square-foot expansion will be developed and…

Psychedelic Clinics Are A Major Vertical That Investors Need To Be Watching

The clinic opportunity is an exciting vertical of the psychedelic industry and is a market that our readers need to be aware of. Last year, the psychedelic clinic market recorded significant advancements, and this is a trend that is expected to continue. We believe the negative mental health effects that…

2 Psychedelic Stocks Thats Are Flying Under The Radar

From the easing of regulations to the reporting of positive clinical trial data, the psychedelic sector is a rapidly evolving industry that is starting to show serious signs of legitimacy. We believe the biggest potential catalyst for the psychedelic sector would be the reporting of positive data from Phase 3…

Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products

Numinus Wellness Inc.  (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), announced today that it has signed a lab services agreement with Optimi Health Corp., developers of a vertically integrated functional mushroom brand focused…

Numinus Wellness Inc. Announces $10 Million Bought Deal Public Offering

Numinus Wellness Inc. (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and Eight Capital. The Underwriters have agreed to purchase,…

Numinus Wellness Is Executing Flawlessly On Their B2B Strategy via Numinus Biosciences

Last month, we issued an update on Numinus Wellness Inc. (TSXV: NUMI) and felt the need to provide an update on the business after it reported a major milestone.  Numinus announced that they have harvested the first legal flush of psilocybe mushrooms in Canada by a public company, out of…

Numinus Wellness Is Building A World Class Psychedelic Research Organization

2020 has been a challenging year for the global economy and the COVID pandemic has made an impact on the mental health market. We believe that the pandemic has served as a catalyst for the psychedelic therapy market as healthcare providers and researchers seek new ways to treat debilitating mental…

Numinus Files Restated Financial Reports

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI) announces that as a result of a review by the Company's auditors in connection with its recently announced prospectus, the Company, on August 24, 2020, has filed restated financial statements (the "Amended Financial Statements") together with a restated management's discussion and analysis (together…

Numinus Wellness Has Big Plans To Scale Operations In The Back Half of 2020 Following A Major License Amendment By Health Canada

Although 2020 has been a challenging year for the global economy, we believe that there are a number of pockets of opportunity that our readers need to be aware of. The psychedelic therapy market has been an emerging opportunity and is an industry that has been generating significant traction. Numinus…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link